Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$146.14 USD

146.14
6,182,473

-0.68 (-0.46%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $145.99 -0.15 (-0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 21% (198 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Ekta Bagri headshot

FDA Demands "Boxed Warning" to CAR T-Cell Therapy Labels

The FDA directs companies like NVS, BMY, GILD and others to add "boxed warning" to the labels of their CAR T-cell immunotherapies after it identified adverse events.

Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

Sector ETF report for IYH

Ethan Feller headshot

Momentum Monday: Inflation, Earnings, and Breakouts

Want to start the week ahead of the pack? Check out Momentum Monday to get the scoop on market-leading stocks and major economic news

Alvotech (ALVO) Up on BLA Update for Two Biosimilar Candidates

The FDA concludes the reinspection of Alvotech's (ALVO) facility in Iceland. The company believes that it may receive approval for biosimilar candidates, AVT02 and AVT04, in the United States. Stock rises.

Sheraz Mian headshot

Q4 Earnings Results Reflect Stability

The picture emerging from the Q4 earnings season thus far has been good enough - not great, but definitely not bad either. Next week, we shift into a much higher gear, with 71 S&P 500 members scheduled to report.

J&J (JNJ) Gears Up to Report Q4 Earnings: What's in Store?

J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.

Wall Street's Insights Into Key Metrics Ahead of Johnson & Johnson (JNJ) Q4 Earnings

Get a deeper insight into the potential performance of Johnson & Johnson (JNJ) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Johnson & Johnson (JNJ) Stock Moves -0.06%: What You Should Know

Johnson & Johnson (JNJ) concluded the recent trading session at $160.43, signifying a -0.06% move from its prior day's close.

Should You Invest in the Vanguard Health Care ETF (VHT)?

Sector ETF report for VHT

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

Kinjel Shah headshot

Pharma Stock Roundup: MRK to Buy Harpoon, JNJ to Acquire Ambrx Biopharma & More

Merck (MRK) offers to acquire Harpoon for $680 million. J&J (JNJ) is set to acquire Ambrx Biopharma for approximately $2.0 billion

The Zacks Analyst Blog Highlights Johnson & Johnson, Micron Technology, The Southern Company, TotalEnergies and PACCAR

Johnson & Johnson, Micron Technology, The Southern Company, TotalEnergies and PACCAR are part of the Zacks top Analyst Blog.

Mark Vickery headshot

Top Analyst Reports for Johnson & Johnson, Micron Technology & Southern Company

Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Micron Technology, Inc. (MU) and The Southern Company (SO).

Sweta Killa headshot

Will Q4 Earnings Push Dow ETF Higher?

Let's delve deeper into the probable fourth-quarter earnings picture that will likely aid Dow ETF in the coming days.

Johnson & Johnson (JNJ) Ascends While Market Falls: Some Facts to Note

The latest trading day saw Johnson & Johnson (JNJ) settling at $161.63, representing a +0.06% change from its previous close.

Ambrx (AMAM) Skyrockets 102% on $2B Buyout Offer From J&J

J&J (JNJ) is set to acquire Ambrx Biopharma (AMAM) in an all-cash transaction for $2.0 billion. The transaction will likely close in first-half 2024.

Sweta Killa headshot

Biotech ETFs Stage Solid Comeback at the Start of 2024

The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-time.

Merck (MRK) to Strengthen Cancer Pipeline With Harpoon Buyout

Merck's (MRK) Harpoon buyout is expected to strengthen its oncology pipeline by adding the latter's lead pipeline candidate, HPN328, a T cell engager being studied for SCLC and neuroendocrine tumors.

Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts

In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $160.97, denoting a +0.63% change from the preceding trading day.

MeiraGTx (MGTX) Stock Surges 35% in a Month: Here's Why

MeiraGTx's (MGTX) shares surge on the sale of rights for a rare ocular disease gene therapy for up to $ 415 million. This funding helps MGTX extend its cash runway into mid-2026.

Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?

Smart Beta ETF report for HDV

Johnson & Johnson (JNJ) Laps the Stock Market: Here's Why

In the most recent trading session, Johnson & Johnson (JNJ) closed at $156.58, indicating a +0.15% shift from the previous trading day.

Is American Century U.S. Quality Value ETF (VALQ) a Strong ETF Right Now?

Smart Beta ETF report for VALQ